AMAG Pharmaceuticals (AMAG) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a hold rating to a buy rating in a research note released on Friday morning.

A number of other research analysts have also recently commented on the stock. Janney Montgomery Scott raised shares of AMAG Pharmaceuticals from a neutral rating to a buy rating and upped their target price for the company from $16.65 to $45.00 in a research report on Thursday, February 15th. B. Riley reaffirmed a hold rating and issued a $16.00 target price on shares of AMAG Pharmaceuticals in a research report on Monday, January 29th. ValuEngine cut shares of AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, February 2nd. Leerink Swann reaffirmed a market perform rating on shares of AMAG Pharmaceuticals in a research report on Friday, February 2nd. Finally, Piper Jaffray reaffirmed a hold rating and issued a $15.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, January 18th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $23.91.

How to Become a New Pot Stock Millionaire

Shares of AMAG stock opened at $20.55 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.60 and a current ratio of 1.74. The stock has a market cap of $700.53, a PE ratio of 97.86 and a beta of 0.09. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $24.85.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.68. AMAG Pharmaceuticals had a negative net margin of 32.66% and a positive return on equity of 0.96%. The company had revenue of $158.30 million for the quarter, compared to analysts’ expectations of $158.84 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. AMAG Pharmaceuticals’s revenue for the quarter was up 4.4% compared to the same quarter last year. analysts forecast that AMAG Pharmaceuticals will post -3.25 earnings per share for the current year.

A number of large investors have recently modified their holdings of AMAG. Sei Investments Co. increased its stake in AMAG Pharmaceuticals by 46.3% during the third quarter. Sei Investments Co. now owns 15,795 shares of the specialty pharmaceutical company’s stock worth $291,000 after purchasing an additional 4,996 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in AMAG Pharmaceuticals by 58.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock worth $243,000 after purchasing an additional 4,870 shares during the period. Macquarie Group Ltd. purchased a new stake in AMAG Pharmaceuticals during the third quarter worth about $266,000. Schroder Investment Management Group increased its stake in AMAG Pharmaceuticals by 101.2% during the third quarter. Schroder Investment Management Group now owns 83,945 shares of the specialty pharmaceutical company’s stock worth $1,490,000 after purchasing an additional 42,233 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in AMAG Pharmaceuticals by 46.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 424,875 shares of the specialty pharmaceutical company’s stock worth $7,839,000 after purchasing an additional 134,080 shares during the period.

COPYRIGHT VIOLATION WARNING: “AMAG Pharmaceuticals (AMAG) Lifted to Buy at BidaskClub” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/amag-pharmaceuticals-amag-lifted-to-buy-at-bidaskclub-2.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply